Observational studyFrontiers in immunology2026
Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.
Xue Peng Rao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.